Skip to main navigation Skip to search Skip to main content

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: Phase I trial results

  • David A. Reardon
  • , Jennifer A. Quinn
  • , Gamal Akabani
  • , R. Edward Coleman
  • , Allan H. Friedman
  • , Henry S. Friedman
  • , James E. Herndon
  • , Roger E. McLendon
  • , Charles N. Pegram
  • , James M. Provenzale
  • , Jeannette M. Dowell
  • , Jeremy N. Rich
  • , James J. Vredenburgh
  • , Annick Desjardins
  • , John H. Sampson
  • , Sridharan Gururangan
  • , Terence Z. Wong
  • , Michael A. Badruddoja
  • , Xiao Guang Zhao
  • , Darell D. Bigner
    • Michael R. Zalutsky

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Fingerprint

Dive into the research topics of 'Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: Phase I trial results'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry